Pseudomonas putida

Publication Title: 
Proceedings of the National Academy of Sciences of the United States of America

Adjustable control of therapeutic transgenes in engineered cell implants after transdermal and topical delivery of nontoxic trigger molecules would increase convenience, patient compliance, and elimination of hepatic first-pass effect in future therapies. Pseudomonas putida DOT-T1E has evolved the flavonoid-triggered TtgR operon, which controls expression of a multisubstrate-specific efflux pump (TtgABC) to resist plant-derived defense metabolites in its rhizosphere habitat. Taking advantage of the TtgR operon, we have engineered a hybrid P.

Gitzinger, Marc
Kemmer, Christian
El-Baba, Marie Daoud
Weber, Wilfried
Fussenegger, Martin
Subscribe to RSS - Pseudomonas putida